Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Chemopreventive and therapeutic effects of Hippophae rhamnoides L. fruit peels evaluated in preclinical models of breast carcinoma

D. Dvorska, D. Sebova, K. Kajo, A. Kapinova, E. Svajdlenka, M. Goga, R. Frenak, J. Treml, S. Mersakova, J. Strnadel, A. Mazurakova, I. Baranova, E. Halasova, M. Brozmanova, K. Biringer, M. Kassayova, Z. Dankova, K. Smejkal, S. Hornak, J. Mojzis,...

. 2025 ; 16 (-) : 1561436. [pub] 20250430

Status not-indexed Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25014454

BACKGROUND: Cancer remains a major global health challenge, necessitating innovative prevention and treatment approaches. Certain plants, adapted to specific environments, may exhibit bioactive properties with potential anticancer applications. HYPOTHESIS: Seaberry (Hippophae rhamnoides L.) fruit peels may exert anticancer effects in breast carcinoma (BC) models through the additive or synergistic actions of their unique secondary metabolites. METHODS: H. rhamnoides fruit peel extracts were analyzed using the LC-DAD-MS and LC-DAD techniques to profile the content of carotenoids and flavonoids, respectively. The preclinical study evaluated seaberry fruit peel extracts in BC models: (1) a syngeneic 4T1 mouse breast adenocarcinoma model (triple-negative), (2) a rat model of chemically induced mammary carcinogenesis, and (3) in vitro studies with MCF-7 (hormone receptor-positive) and MDA-MB-231 (triple-negative) BC cell lines. RESULTS: LC-DAD-MS and LC-DAD analyses identified dominant metabolites, including isorhamnetin, quercetin glycosides, kaempferol glycosides, catechin, zeaxanthin, and lutein. In the 4T1 mouse model, seaberry treatment resulted in a significant, dose-dependent reduction in tumor volume (43% and 48% compared to controls) and a decrease in the mitotic activity index. Serum cytokine analysis showed dose-dependent reductions in IL-6, IL-10, and TNF-α. In the rat chemopreventive model, high-dose seaberry improved cancer prognosis by reducing the ratio of poorly differentiated tumors and increasing caspase-3 and Bax expression while decreasing Ki-67 and malondialdehyde levels. Both treatment doses elevated the Bax/Bcl-2 ratio and reduced the expression of cancer stem cell markers CD44, EpCam, and VEGF compared to controls. Epigenetic analyses revealed histone modifications (H4K16ac, H4K20me3) and altered methylation of tumor-suppressor genes (PITX2, RASSF1, PTEN, TIMP3). Microarray analysis (758 miRNAs) identified beneficial changes in nine oncogenic/tumor-suppressive miRNAs, including miR-10a-5p, miR-322-5p, miR-450a-5p, miR-142-5p, miR-148b-3p, miR-1839-3p, miR-18a-5p, miR-1949, and miR-347. In vitro, ethanolic seaberry extract conferred partial resistance to cisplatin-induced cytotoxicity in MCF-7 and MDA-MB-231 cells at IC50 concentrations. CONCLUSION: This study of H. rhamnoides in rodent BC models shows promising data but requires rigorous, long-term validation. Integrating plant-based nutraceuticals into oncology necessitates precise cancer-type profiling and patient stratification for effective personalized treatments.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25014454
003      
CZ-PrNML
005      
20250905141326.0
007      
ta
008      
250701e20250430sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2025.1561436 $2 doi
035    __
$a (PubMed)40371330
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Dvorska, Dana $u Biomedical Centre Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
245    10
$a Chemopreventive and therapeutic effects of Hippophae rhamnoides L. fruit peels evaluated in preclinical models of breast carcinoma / $c D. Dvorska, D. Sebova, K. Kajo, A. Kapinova, E. Svajdlenka, M. Goga, R. Frenak, J. Treml, S. Mersakova, J. Strnadel, A. Mazurakova, I. Baranova, E. Halasova, M. Brozmanova, K. Biringer, M. Kassayova, Z. Dankova, K. Smejkal, S. Hornak, J. Mojzis, V. Sadlonova, D. Brany, M. Kello, P. Kubatka
520    9_
$a BACKGROUND: Cancer remains a major global health challenge, necessitating innovative prevention and treatment approaches. Certain plants, adapted to specific environments, may exhibit bioactive properties with potential anticancer applications. HYPOTHESIS: Seaberry (Hippophae rhamnoides L.) fruit peels may exert anticancer effects in breast carcinoma (BC) models through the additive or synergistic actions of their unique secondary metabolites. METHODS: H. rhamnoides fruit peel extracts were analyzed using the LC-DAD-MS and LC-DAD techniques to profile the content of carotenoids and flavonoids, respectively. The preclinical study evaluated seaberry fruit peel extracts in BC models: (1) a syngeneic 4T1 mouse breast adenocarcinoma model (triple-negative), (2) a rat model of chemically induced mammary carcinogenesis, and (3) in vitro studies with MCF-7 (hormone receptor-positive) and MDA-MB-231 (triple-negative) BC cell lines. RESULTS: LC-DAD-MS and LC-DAD analyses identified dominant metabolites, including isorhamnetin, quercetin glycosides, kaempferol glycosides, catechin, zeaxanthin, and lutein. In the 4T1 mouse model, seaberry treatment resulted in a significant, dose-dependent reduction in tumor volume (43% and 48% compared to controls) and a decrease in the mitotic activity index. Serum cytokine analysis showed dose-dependent reductions in IL-6, IL-10, and TNF-α. In the rat chemopreventive model, high-dose seaberry improved cancer prognosis by reducing the ratio of poorly differentiated tumors and increasing caspase-3 and Bax expression while decreasing Ki-67 and malondialdehyde levels. Both treatment doses elevated the Bax/Bcl-2 ratio and reduced the expression of cancer stem cell markers CD44, EpCam, and VEGF compared to controls. Epigenetic analyses revealed histone modifications (H4K16ac, H4K20me3) and altered methylation of tumor-suppressor genes (PITX2, RASSF1, PTEN, TIMP3). Microarray analysis (758 miRNAs) identified beneficial changes in nine oncogenic/tumor-suppressive miRNAs, including miR-10a-5p, miR-322-5p, miR-450a-5p, miR-142-5p, miR-148b-3p, miR-1839-3p, miR-18a-5p, miR-1949, and miR-347. In vitro, ethanolic seaberry extract conferred partial resistance to cisplatin-induced cytotoxicity in MCF-7 and MDA-MB-231 cells at IC50 concentrations. CONCLUSION: This study of H. rhamnoides in rodent BC models shows promising data but requires rigorous, long-term validation. Integrating plant-based nutraceuticals into oncology necessitates precise cancer-type profiling and patient stratification for effective personalized treatments.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sebova, Dominika $u Department of Pharmacology, Faculty of Medicine, P. J. Šafárik University, Košice, Slovakia
700    1_
$a Kajo, Karol $u Department of Pathology, St. Elisabeth Oncology Institute, Bratislava, Slovakia
700    1_
$a Kapinova, Andrea $u Biomedical Centre Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Svajdlenka, Emil $u Department of Natural Drugs, Faculty of Pharmacy, Masaryk University, Brno, Czechia
700    1_
$a Goga, Michal $u Department of Botany, Institute of Biology and Ecology, Faculty of Science, P. J. Safarik University, Kosice, Slovakia
700    1_
$a Frenak, Richard $u Department of Botany, Institute of Biology and Ecology, Faculty of Science, P. J. Safarik University, Kosice, Slovakia
700    1_
$a Treml, Jakub $u Department of Molecular Pharmacy, Faculty of Pharmacy, Masaryk University, Brno, Czechia
700    1_
$a Mersakova, Sandra $u Biomedical Centre Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Strnadel, Jan $u Biomedical Centre Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Mazurakova, Alena $u Department of Anatomy, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Baranova, Ivana $u Department of Pathological Physiology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia $u Biobank for Cancer and Rare Diseases, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Halasova, Erika $u Biomedical Centre Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Brozmanova, Mariana $u Department of Pathological Physiology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Biringer, Kamil $u Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Kassayova, Monika $u Department of Animal Physiology, Institute of Biology and Ecology, Faculty of Science, P. J. Safarik University, Kosice, Slovakia
700    1_
$a Dankova, Zuzana $u Biomedical Centre Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia $u Biobank for Cancer and Rare Diseases, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Smejkal, Karel $u Department of Natural Drugs, Faculty of Pharmacy, Masaryk University, Brno, Czechia
700    1_
$a Hornak, Slavomir $u Small Animal Clinic, University of Veterinary Medicine and Pharmacy, Kosice, Slovakia
700    1_
$a Mojzis, Jan $u Department of Pharmacology, Faculty of Medicine, P. J. Šafárik University, Košice, Slovakia
700    1_
$a Sadlonova, Vladimira $u Department of Microbiology and Immunology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Brany, Dusan $u Biomedical Centre Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Kello, Martin $u Department of Pharmacology, Faculty of Medicine, P. J. Šafárik University, Košice, Slovakia
700    1_
$a Kubatka, Peter $u Laboratory of Experimental and Clinical Regenerative Medicine, Small Animal Clinic, University of Veterinary Medicine and Pharmacy, Kosice, Slovakia
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 16 (20250430), s. 1561436
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40371330 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250701 $b ABA008
991    __
$a 20250905141314 $b ABA008
999    __
$a ok $b bmc $g 2388089 $s 1251574
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 16 $c - $d 1561436 $e 20250430 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20250701

Find record

Citation metrics

Archiving options